144 related articles for article (PubMed ID: 16149069)
1. Optimized transfection of diced siRNA into mature primary human osteoclasts: inhibition of cathepsin K mediated bone resorption by siRNA.
Selinger CI; Day CJ; Morrison NA
J Cell Biochem; 2005 Dec; 96(5):996-1002. PubMed ID: 16149069
[TBL] [Abstract][Full Text] [Related]
2. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
3. Effects of antisense mediated inhibition of cathepsin K on human osteoclasts obtained from peripheral blood.
Avnet S; Lamolinara A; Zini N; Solimando L; Quacquaruccio G; Granchi D; Maraldi NM; Giunti A; Baldini N
J Orthop Res; 2006 Aug; 24(8):1699-708. PubMed ID: 16795033
[TBL] [Abstract][Full Text] [Related]
4. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
Dodds RA; James IE; Rieman D; Ahern R; Hwang SM; Connor JR; Thompson SD; Veber DF; Drake FH; Holmes S; Lark MW; Gowen M
J Bone Miner Res; 2001 Mar; 16(3):478-86. PubMed ID: 11277265
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Schurigt U; Hummel KM; Petrow PK; Gajda M; Stöckigt R; Middel P; Zwerina J; Janik T; Bernhardt R; Schüler S; Scharnweber D; Beckmann F; Saftig P; Kollias G; Schett G; Wiederanders B; Bräuer R
Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
[TBL] [Abstract][Full Text] [Related]
6. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells.
Pang M; Martinez AF; Fernandez I; Balkan W; Troen BR
Gene; 2007 Nov; 403(1-2):151-8. PubMed ID: 17897792
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.
Morko J; Kiviranta R; Mulari MT; Ivaska KK; Väänänen HK; Vuorio E; Laitala-Leinonen T
Bone; 2009 Apr; 44(4):717-28. PubMed ID: 19118660
[TBL] [Abstract][Full Text] [Related]
8. Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis.
Knowles HJ; Athanasou NA
J Pathol; 2009 Jun; 218(2):256-64. PubMed ID: 19291710
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Ulmus davidiana Planch (Ulmaceae) on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts.
Kim KW; Park JS; Kim KS; Jin UH; Kim JK; Suh SJ; Kim CH
Phytother Res; 2008 Apr; 22(4):511-7. PubMed ID: 18338784
[TBL] [Abstract][Full Text] [Related]
10. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
11. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
12. Cystatin B as an intracellular modulator of bone resorption.
Laitala-Leinonen T; Rinne R; Saukko P; Väänänen HK; Rinne A
Matrix Biol; 2006 Apr; 25(3):149-57. PubMed ID: 16321512
[TBL] [Abstract][Full Text] [Related]
13. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
Xia L; Kilb J; Wex H; Li Z; Lipyansky A; Breuil V; Stein L; Palmer JT; Dempster DW; Brömme D
Biol Chem; 1999 Jun; 380(6):679-87. PubMed ID: 10430032
[TBL] [Abstract][Full Text] [Related]
14. The regulation of cathepsin K gene expression.
Troen BR
Ann N Y Acad Sci; 2006 Apr; 1068():165-72. PubMed ID: 16831915
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix-degrading cysteine proteinase cathepsin K in cholesteatoma.
Hansen T; Unger RE; Gaumann A; Hundorf I; Maurer J; Kirkpatrick CJ; Kriegsmann J
Mod Pathol; 2001 Dec; 14(12):1226-31. PubMed ID: 11743044
[TBL] [Abstract][Full Text] [Related]
16. Human osteoblasts produce cathepsin K.
Mandelin J; Hukkanen M; Li TF; Korhonen M; Liljeström M; Sillat T; Hanemaaijer R; Salo J; Santavirta S; Konttinen YT
Bone; 2006 Jun; 38(6):769-77. PubMed ID: 16337236
[TBL] [Abstract][Full Text] [Related]
17. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
Duplat D; Gallet M; Berland S; Marie A; Dubost L; Rousseau M; Kamel S; Milet C; Brazier M; Lopez E; Bédouet L
Biomaterials; 2007 Nov; 28(32):4769-78. PubMed ID: 17686515
[TBL] [Abstract][Full Text] [Related]
18. Application of small interfering RNA for inhibition of lipopolysaccharide-induced osteoclast formation and cytokine stimulation.
Fahid FS; Jiang J; Zhu Q; Zhang C; Filbert E; Safavi KE; Spångberg LS
J Endod; 2008 May; 34(5):563-9. PubMed ID: 18436035
[TBL] [Abstract][Full Text] [Related]
19. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
20. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]